STAT3 and breast cancer: The downregulation of ASRPS (a STAT3 small regulatory peptide) in triple-negative BC cells has been associated with poor overall survival; this peptide downregulated STAT3 phosphorylation and reduced angiogenesis in an experimental animal model of BC; ASRPS downregulation favored tumor growth and the peptide acted as an anticancer peptide in in vivo experiments [250].